GlassScriptPhysician profile
Amy R Jackson
NPI 1467019943
$1,827.30
in general payments reported to CMS, 2019-2025
17 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.76 · 2023: $191 · 2024: $338 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454 · Travel and Lodging: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.46 |
| Travel and Lodging | $331.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $637.30 | 2025 | Minimed 780g |
| Insulet Corporation | $341.86 | 2024-2025 | Omnipod |
| Sequel Med Tech, LLC | $240.81 | 2025 | Twiist |
| Novo Nordisk INC | $161.98 | 2022-2025 | Ozempic, Wegovy |
| Corcept Therapeutics | $102.26 | 2023-2025 | Korlym |
| Lilly USA, LLC | $58.91 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $47.88 | 2023 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.02 | 2023 | Jardiance |
| Abbvie INC. | $30.00 | 2023 | |
| Dexcom, INC. | $25.49 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $24.81 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.85 | 2025 | |
| Echosens North America, INC. | $19.13 | 2025 | Fibroscan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.07 | 2025 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $18.72 | 2023 | Nexplanon |
| Amgen INC. | $14.99 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.